Prellis Biologics key facts
as of Oct 2026- Developer of a bioprinting technology designed to recreate and engineer human tissues in vitro.
- Prellis Biologics is valued at approximately $110.1M as of Oct 2026, set at its later-stage round, Nov 2023; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $70.2M across 5 recorded rounds; the latest was Early Stage VC ($17.0M) in Jun 2022.
- Notable investors include Plug and Play Tech Center, SOSV, Khosla Ventures, IndieBio, True Ventures — 16 tracked in total.
- Prellis Biologics has filed 5 Form Ds with the SEC since 2017, most recently Jul 2022 ($17.0M sold to 19 investors).
- Status: Privately Held (backing).
Valued at $110.1M at its later-stage round, Nov 2023. Nothing has traded since.
- ·The complete investor list: 16 names
- ·Watch Prellis Biologics: the Monday email on marks, rounds and moves
Prellis Biologics funding rounds
5 roundsWho backs Prellis Biologics
16+Prellis Biologics valuation
Prellis Biologics was valued at $110 million at its later-stage round in Nov 2023. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Prellis Biologics raised?
Prellis Biologics has raised $70.2 million across 5 recorded rounds since 2017. The largest was an $8.7 million early-stage round in Mar 2019; the most recent was a $17 million early-stage round in Jun 2022.
Prellis Biologics has filed 5 Form Ds with the SEC since 2017, most recently in Jul 2022 ($17 million sold to 19 investors).
Prellis Biologics investors
16 investors are on record for Prellis Biologics, including Plug and Play Tech Center, SOSV, Khosla Ventures and IndieBio. By type, the record holds 8 venture capital firms and 1 asset manager. The early-stage round in Jun 2022 drew 19 investors.
About Prellis Biologics
Developer of a bioprinting technology designed to recreate and engineer human tissues in vitro. The company's technology precisely reproduces the human immune response through the creation of lymph node organoids and can exploit fully human immune responses for a variety of applications, including antibody discovery, immunogenicity assessment, and tumor-immune models, improving patients' lives by addressing challenges commonly faced in early-stage drug discovery and translational pharmacology.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2016
- Employees
- 50
- Website
- prellisbio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.